Rosebud Biosciences
Rosebud Biosciences, based in California, accelerates drug development by using patented organoid technology to model genetic diseases and screen drugs, focusing on rare pediatric conditions.
Company Overview
Rosebud Biosciences, formerly known as Rosebud Biosciences Inc., operates in the healthcare industry, specifically within the therapeutics sub-industry. The company is based in San Francisco and San Carlos, California. With a small team of three, the company focuses on accelerating drug development by screening drugs against organoids mirroring gene mutations in patients. It partners with therapeutics companies for drug screening and also engages in its own drug discovery projects.
Drug Discovery and Therapeutic Development
Rosebud Biosciences specializes in developing therapies for rare genetic diseases affecting children. By creating organoids that model human development, the company hopes to discover novel drug targets, potentially offering higher success rates than traditional adult disease models. The company's patented platform integrates organoids, machine learning, and molecular advancements to provide quick, accurate, and scalable modeling of genetic diseases. This approach aims to reduce the cost and time required for pre-clinical testing.
Partnerships and Collaborations
Rosebud Biosciences seeks partnerships with pharmaceutical companies to carry out pilot projects in developing drug therapies for heart and liver diseases. By collaborating with these companies, Rosebud Biosciences screens their drugs using its advanced organoid technology, aiming to discover effective treatments for diseases that currently have no existing solutions. Active collaboration initiatives are a core aspect of Rosebud Biosciences' operational strategy.
Technological Innovations
The technology utilized by Rosebud Biosciences was validated at Stanford and has been published in a prestigious journal. The company discovered a drug target for pediatric heart disease using its pioneering technology. Its organoid platform is fetal-like, providing unique opportunities for discovering novel drug targets in pediatric diseases. This approach is distinct from traditional models, as it focuses on human development rather than degeneration. Rosebud claims this could lead to significantly higher success rates.
Y-Combinator Involvement
Rosebud Biosciences was part of the Winter 2022 (W22) batch of Y-Combinator, a well-known startup accelerator. The company leveraged this opportunity to further develop its innovative drug discovery technologies and expand its network within the therapeutics sector.